Motavizumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameMotavizumab
Drug Alias Name莫维珠单抗莫他韦珠单抗NumaxRezieldMEDI-524
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionRespiratory syncytial virus F protein inhibitors
TargetsRespiratory syncytial virus F protein
Therapy Area/IndicationsRespiratory SoundsHeart Defects, CongenitalLung Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[26] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedimmune Llc
Active IndicationsN/A
Inactive IndicationsRespiratory SoundsHeart Defects, CongenitalLung Diseases +[4] 

Other Information

ATC CodeJ06BB17
Related LinksWikipediaKEGG